Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12;214(2):144-153.
doi: 10.1093/cei/uxad102.

MAIT cells in bacterial infectious diseases: heroes, villains, or both?

Affiliations
Review

MAIT cells in bacterial infectious diseases: heroes, villains, or both?

Sihong Wu et al. Clin Exp Immunol. .

Abstract

Due to the aggravation of bacterial drug resistance and the lag in the development of new antibiotics, it is crucial to develop novel therapeutic regimens for bacterial infectious diseases. Currently, immunotherapy is a promising regimen for the treatment of infectious diseases. Mucosal-associated invariant T (MAIT) cells, a subpopulation of innate-like T cells, are abundant in humans and can mount a rapid immune response to pathogens, thus becoming a potential target of immunotherapy for infectious diseases. At the site of infection, activated MAIT cells perform complex biological functions by secreting a variety of cytokines and cytotoxic substances. Many studies have shown that MAIT cells have immunoprotective effects because they can bridge innate and adaptive immune responses, leading to bacterial clearance, tissue repair, and homeostasis maintenance. MAIT cells also participate in cytokine storm generation, tissue fibrosis, and cancer progression, indicating that they play a role in immunopathology. In this article, we review recent studies of MAIT cells, discuss their dual roles in bacterial infectious diseases and provide some promising MAIT cell-targeting strategies for the treatment of bacterial infectious diseases.

Keywords: MAIT cells; bacterial infectious disease; immunopathology; immunoprotection; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Mucosal-associated invariant T (MAIT) cells in bacterial infectious diseases. In bacterial infectious diseases, pathogens or riboflavin metabolisms are captured by antigen-presenting cells (APCs), which can activate MAIT cells in a TCR-dependent manner or cytokine (CK)-dependent manner. Upon activation, MAIT cells proliferate, secrete abundant cytokines, and then recruit and activate other immune cells, acting as a bridge to link innate and adaptive immunity. Activated MAIT cells act as heroes, villains, or both in different bacterial infectious diseases.

Similar articles

Cited by

References

    1. Collaborators GDaIIaP. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–858. doi:10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed
    1. Collaborators GDaI. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–22. doi:10.1016/S0140-6736(20)30925-9 - DOI - PMC - PubMed
    1. Furuya EY, Lowy FD.. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol 2006, 4, 36–45. doi:10.1038/nrmicro1325 - DOI - PubMed
    1. Tang SS, Apisarnthanarak A, Hsu LY.. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev 2014, 78, 3–13. doi:10.1016/j.addr.2014.08.003 - DOI - PubMed
    1. Jernigan JA, Hatfield KM, Wolford H, Nelson RE, Olubajo B, Reddy SC, et al. . Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N Engl J Med 2020, 382, 1309–19. doi:10.1056/NEJMoa1914433 - DOI - PMC - PubMed

Publication types